Galderma’s Nemluvio shows itch reduction in 48 hours
Galderma’s dermatology monoclonal antibody (mAb) Nemluvio (nemolizumab) has shown proof of improving symptoms of atopic dermatitis (AD) and prurigo nodularis…
Latest News
-
-
Padcev-Keytruda notches another Phase III win in bladder cancer
A combination of Pfizer and Astellas’ Padcev (enfortumab vedotin) and MSD’s Keytruda (pembrolizumab) has offered significant improvements to patient outcomes…
-
4DMT’s gene therapy hopeful for cystic fibrosis shows promise in Phase I trial
4D Molecular Therapeutics (4DMT) is pressing ahead with evaluation of its gene therapy, 4D-710, in a Phase II dose expansion…
-
DBV to make new approval bid for VIASKIN Peanut on Phase III trial
DBV Technologies will be making another attempt at gaining US Food and Drug Administration (FDA) approval for its peanut allergy…
-
Aviceda Therapeutics to advance eye disease drug despite Phase IIb loss
Aviceda Therapeutics’ eye disease drug will advance to Phase III, despite it failing to meet the primary endpoint in a…
-
Immunome seeks GSI inhibitor market entry on Phase III desmoid tumour win
Immunome is seeking US approval for its gamma secretase inhibitor (GSI) for the treatment of desmoid tumours after the drug…
-
InnoCare’s BTK inhibitor advances to Phase III in SLE
InnoCare Pharma’s orelabrutinib is progressing to a pivotal trial in systemic lupus erythematosus (SLE) after the drug displayed encouraging activity…
-
Lilly’s triple G agonist boasts 28.7% weight loss in Phase III trial
Eli Lilly’s triple glucagon agonist has achieved up to 28.7% weight loss in a Phase III trial. In the TRIUMPH-4…
-
GRI Bio’s tazarotene achieves Phase IIa IPF success
GRI Bio’s lead candidate, tazarotene, has exhibited disease-modifying potential in a mid-stage study in idiopathic pulmonary fibrosis (IPF). In the…
-
BioNTech and BMS’ bispecific touts 59.3% nine-month PFS in TNBC
Bristol Myers Squibb (BMS) and BioNTech's pumitamig has displayed promising efficacy and safety during a mid-stage trial in front and…
